Warning! GuruFocus detected
1 Medium warning sign
with KNSA.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Kiniksa Pharmaceuticals International PLC
NAICS : 325412
SIC : 2833
ISIN : GB00BRXB0C07
Share Class Description:
KNSA: Class ACompare
Compare
Traded in other countries / regions
KNSA.USA Index Membership
Russell 2000Russell 3000 IPO Date
2018-05-24Description
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 24.72 | |||||
| Equity-to-Asset | 0.76 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.22 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 5.95 | |||||
| Beneish M-Score | -2.46 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 119.3 | |||||
| 3-Year EBITDA Growth Rate | 35.1 | |||||
| 3-Year EPS without NRI Growth Rate | 36.1 | |||||
| 3-Year Book Growth Rate | 31.2 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 24.02 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 14.06 | |||||
| 9-Day RSI | 27.89 | |||||
| 14-Day RSI | 37.15 | |||||
| 3-1 Month Momentum % | 5.02 | |||||
| 6-1 Month Momentum % | -12.87 | |||||
| 12-1 Month Momentum % | 18.11 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.3 | |||||
| Quick Ratio | 3.04 | |||||
| Cash Ratio | 2.42 | |||||
| Days Inventory | 177.74 | |||||
| Days Sales Outstanding | 21.44 | |||||
| Days Payable | 37.92 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.6 | |||||
| Shareholder Yield % | 0.35 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 85.61 | |||||
| Operating Margin % | -10.78 | |||||
| Net Margin % | -10.21 | |||||
| FCF Margin % | 6.05 | |||||
| ROE % | -9.9 | |||||
| ROA % | -7.93 | |||||
| ROIC % | -19.76 | |||||
| 3-Year ROIIC % | 44.3 | |||||
| ROC (Joel Greenblatt) % | -328.79 | |||||
| ROCE % | -9.85 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 36.49 | |||||
| PS Ratio | 3.45 | |||||
| PB Ratio | 3.37 | |||||
| Price-to-Tangible-Book | 3.5 | |||||
| Price-to-Free-Cash-Flow | 57.12 | |||||
| Price-to-Operating-Cash-Flow | 56.97 | |||||
| EV-to-EBIT | -29.51 | |||||
| EV-to-EBITDA | -30.65 | |||||
| EV-to-Revenue | 3.18 | |||||
| EV-to-FCF | 52.58 | |||||
| Price-to-GF-Value | 0.6 | |||||
| Price-to-Net-Current-Asset-Value | 7.77 | |||||
| Price-to-Net-Cash | 14.54 | |||||
| Earnings Yield (Greenblatt) % | -3.39 | |||||
| FCF Yield % | 1.73 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:KNSA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Kiniksa Pharmaceuticals International PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 423.239 | ||
| EPS (TTM) ($) | -0.61 | ||
| Beta | 0.15 | ||
| 3-Year Sharpe Ratio | 0.58 | ||
| 3-Year Sortino Ratio | 1.37 | ||
| Volatility % | 48.45 | ||
| 14-Day RSI | 37.15 | ||
| 14-Day ATR ($) | 0.868467 | ||
| 20-Day SMA ($) | 22.4625 | ||
| 12-1 Month Momentum % | 18.11 | ||
| 52-Week Range ($) | 16.56 - 28.15 | ||
| Shares Outstanding (Mil) | 72.64 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Kiniksa Pharmaceuticals International PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Kiniksa Pharmaceuticals International PLC Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Kiniksa Pharmaceuticals International PLC Frequently Asked Questions
What is Kiniksa Pharmaceuticals International PLC(KNSA)'s stock price today?
The current price of KNSA is $20.35. The 52 week high of KNSA is $28.15 and 52 week low is $16.56.
When is next earnings date of Kiniksa Pharmaceuticals International PLC(KNSA)?
The next earnings date of Kiniksa Pharmaceuticals International PLC(KNSA) is 2025-04-23 Est..
Does Kiniksa Pharmaceuticals International PLC(KNSA) pay dividends? If so, how much?
Kiniksa Pharmaceuticals International PLC(KNSA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers